Morris Laster
Director/Board Member at SCINAI IMMUNOTHERAPEUTICS LTD.
Net worth: 5 001 $ as of 29/04/2024
Morris Laster active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SCINAI IMMUNOTHERAPEUTICS LTD. | Director/Board Member | 26/11/2017 | - |
| Independent Dir/Board Member | 26/11/2017 | - | |
Dynamix Pharmaceuticals Ltd.
 Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | Director/Board Member | 20/04/2010 | - |
| Clil Medical Ltd. | Chief Executive Officer | - | - |
Ourcrowd Medtech Fund
 Ourcrowd Medtech Fund Investment ManagersFinance OurCrowd Medtech Fund invests in companies located in Israel. The fund targets operating in the fields of medical devices, therapeutics, medical robotics. It provides financing for early stage capital requirements. | Corporate Officer/Principal | 30/06/2013 | - |
Dreamed Diabetes Ltd.
 Dreamed Diabetes Ltd. Packaged SoftwareTechnology Services DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014. | Director/Board Member | - | - |
BrainQ Technologies Ltd.
 BrainQ Technologies Ltd. Packaged SoftwareTechnology Services BrainQ Technologies Ltd. develops a detection and non-invasive treatment technology to help patients with paralysis move their limbs. The company was founded by Segal Yaron, Drechsler Yotam, and Shohami Emerita Esther on August 14, 2011 and is headquartered in Jerusalem, Israel. | Director/Board Member | - | - |
Nanolabz, Inc.
 Nanolabz, Inc. Medical SpecialtiesHealth Technology Nanolabz, Inc. develops a technology system for cancer proton radiation therapy. It develops and sells laser physics targets for the short-pulse laser research and development sector. The company was founded by Steven Malekos, Jesse Adams, and Grant Korgan and is headquartered in Sparks, NV. | Director/Board Member | - | - |
HIL Applied Medical Ltd.
 HIL Applied Medical Ltd. Medical SpecialtiesHealth Technology HIL Applied Medical Ltd. develops cancer Proton Therapy systems. It applies a patented approach, combining nanotechnology, and high-intensity lasers for its solutions. The company was founded by Shmuel Eisenmann and Arie Zigler in 2010 and is headquartered in Jerusalem, Israel. | Director/Board Member | - | - |
OurCrowd Management Ltd.
 OurCrowd Management Ltd. Investment ManagersFinance OurCrowd Management Ltd (OurCrowd Management) is a venture capital firm and equity based crowdfunding platform founded in 2013 by Jonathan Medved and Steven Blumgart. The firm is headquartered in Jerusalem, Israel. | Private Equity Investor | 30/06/2013 | - |
Career history of Morris Laster
Former positions of Morris Laster
| Companies | Position | Start | End |
|---|---|---|---|
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ | - | - | |
| ░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░ ░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ | ░░░░░░░░░░ | - |
Training of Morris Laster
| State University of New York at Downstate Medical Center | Doctorate Degree |
| State University of New York at Albany | Undergraduate Degree |
Statistics
International
| Israel | 15 |
| United States | 8 |
Operational
| Director/Board Member | 9 |
| Founder | 6 |
| Chief Executive Officer | 4 |
Sectoral
| Health Technology | 13 |
| Consumer Services | 3 |
| Technology Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| PURPLE BIOTECH LTD | Health Technology |
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| SCINAI IMMUNOTHERAPEUTICS LTD. | Health Technology |
| SCOPUS BIOPHARMA INC. | Health Technology |
| Private companies | 14 |
|---|---|
Dynamix Pharmaceuticals Ltd.
Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | Health Technology |
C.G.M.3 Ltd.
 C.G.M.3 Ltd. Medical SpecialtiesHealth Technology C.G.M.3 Ltd is an early-stage medical company that was founded in 2007 and joined NAIOT Venture Accelerator, at Yokneam, Israel in 2009, as a seed company. C.G.M.3 Ltd is developing a miniaturized implantable device which utilizes a groundbreaking solution for reliable, real- time, long-term Continuous Glucose Monitoring (CGM). The device will ultimately offer a true resolution and improved quality of life for diabetes patients. In fact, C.G.M.3 solution presents the missing link towards a potent closed-loop artificial pancreas. | Health Technology |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
| Paramount Capital Investments LLC | |
HIL Applied Medical Ltd.
HIL Applied Medical Ltd. Medical SpecialtiesHealth Technology HIL Applied Medical Ltd. develops cancer Proton Therapy systems. It applies a patented approach, combining nanotechnology, and high-intensity lasers for its solutions. The company was founded by Shmuel Eisenmann and Arie Zigler in 2010 and is headquartered in Jerusalem, Israel. | Health Technology |
Xerem Medical Ltd.
 Xerem Medical Ltd. Medical SpecialtiesHealth Technology Xerem Medical Ltd. develops long-term implant for circulatory purposes, specifically, hemodialysis. The company was founded by Morris C. Laster in 2015 and is headquartered in Tel Aviv, Israel. | Health Technology |
Nanolabz, Inc.
Nanolabz, Inc. Medical SpecialtiesHealth Technology Nanolabz, Inc. develops a technology system for cancer proton radiation therapy. It develops and sells laser physics targets for the short-pulse laser research and development sector. The company was founded by Steven Malekos, Jesse Adams, and Grant Korgan and is headquartered in Sparks, NV. | Health Technology |
BrainQ Technologies Ltd.
BrainQ Technologies Ltd. Packaged SoftwareTechnology Services BrainQ Technologies Ltd. develops a detection and non-invasive treatment technology to help patients with paralysis move their limbs. The company was founded by Segal Yaron, Drechsler Yotam, and Shohami Emerita Esther on August 14, 2011 and is headquartered in Jerusalem, Israel. | Technology Services |
Dreamed Diabetes Ltd.
Dreamed Diabetes Ltd. Packaged SoftwareTechnology Services DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014. | Technology Services |
Ourcrowd Medtech Fund
Ourcrowd Medtech Fund Investment ManagersFinance OurCrowd Medtech Fund invests in companies located in Israel. The fund targets operating in the fields of medical devices, therapeutics, medical robotics. It provides financing for early stage capital requirements. | Finance |
OncoHost Ltd.
 OncoHost Ltd. Miscellaneous Commercial ServicesCommercial Services OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon. | Commercial Services |
| Clil Medical Ltd. | |
OurCrowd Management Ltd.
OurCrowd Management Ltd. Investment ManagersFinance OurCrowd Management Ltd (OurCrowd Management) is a venture capital firm and equity based crowdfunding platform founded in 2013 by Jonathan Medved and Steven Blumgart. The firm is headquartered in Jerusalem, Israel. | Finance |
- Stock Market
- Insiders
- Morris Laster
- Experience
